Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody | BMC Cancer | Full Text

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody | BMC Cancer | Full Text

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) are used for the treatment of various cancer types. However, immune-related adverse events (irAEs) occur in patients treated...

Authors:Hiroshi Matsuoka, Takahiro Hayashi, Karen Takigami, Kazuyoshi Imaizumi, Ryoichi Shiroki, Naoki Ohmiya, Kazumitsu Sugiura, Kenji Kawada, Akira Sawaki, Koutaro Maeda, Yousuke Ando and Ichiro Uyama

Citation:BMC Cancer 2020 20:656

Content type:Research article

 

Published on: 14 July 2020

• ViewFull Text
 
• ViewPDF